

primary studies - published RCT

## **Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis.**

**Code:** PM20953746

**Year:** 2010 **Date:** 2014

**Author:** Buonpensiero P

### **Study design (if review, criteria of inclusion for studies)**

Randomized, open-label, multicentre, two-period, crossover study

### **Participants**

58 patients with CF and chronic *Pseudomonas aeruginosa* (PA) infection

### **Interventions**

two tobramycin nebuliser solutions: T100/eFlow or TNS/PARI LC PLUS.

### **Outcome measures**

The primary objective was to demonstrate the equivalence of both treatments with respect to pharmacokinetics (area under the concentration-time curve and maximum concentration in plasma). Secondary endpoints were tobramycin sputum pharmacokinetics, reduction in PA colony forming units, improvement of lung function, incidence of adverse drug reactions and reduction of inhalation times.

### **Main results**

Tobramycin plasma AUC and Cmax were lower after administration of T100 than after TNS. The study failed to demonstrate systemic bioequivalence of the two treatments. After T100 administration, tobramycin sputum AUC and Cmax achieved higher values than after TNS. Changes in efficacy parameters from baseline were similar. Safety profiles were not different or unexpected. Inhalation time per inhalation was shorter during treatment with T100.

### **Authors' conclusions**

The lower systemic drug burden and the higher local drug deposition together with a comparable efficacy/safety profile and a shorter inhalation time render T100/eFlow an attractive treatment option for CF patients.

<http://dx.doi.org/10.1007/s12325-010-0076-8>

### **See also**

Adv Ther. 2010 Nov;27(11):870-8. Epub 2010 Oct 14.

### **Keywords**

Anti-Bacterial Agents; *Pseudomonas aeruginosa*; *Pseudomonas*; Tobramycin; Bacterial Infections; Infection; Inhalation OR nebulised; nebuliser; non pharmacological intervention - devices OR physiotherapy; pharmacological\_intervention; Respiratory Tract Diseases; Respiratory Tract Infections; Airway clearance technique; Vibration; Aminoglycosides; oscillating devices; Chest physiotherapy;